Four guardians email format

JV Opportunity to Complete the Registration of an Innovative Child and Adult Friendly HIV /AIDS and further assessment of against the Human Coronavirus. This Prodrug drug can be readily formulated for children as well as victims of all ages, who are suffering and dying from this chronic and cruel disease before their time and whose current treatment may be less than optimal. With my team, we have been able to secure the global IP and ownership rights of an anti-viral drug, DG35/17 Prodrug, the development of which Narhex Australia has been instrumental for many years. This is now established in a newly founded Australian company - Four Guardians Pty Ltd. Four Guardians are seeking JV Biotech partners or investors to complete the remaining clinical trials and to partner in taking this drug to market. The clinical trial process for DG35/17 Prodrug is more than 70% completed for drug market registration and is thus well progressed towards commercialisation. All clinical results and technical studies have clearly and unambiguously demonstrated its effectiveness in the treatment of HIV / AIDS and in the absence of toxic side effects, which affects many current forms of treatment. The development of DG35/17 Prodrug, unlike other Protease inhibitors, has benefited from a successful and proven development track record through substantive clinical studies and human trials. Next stage of development, DG 35 will undergo further in vitro screening against influenza, RSV, PIV, human rhinovirus or the human Coronavirus. As past assessments merit full antiviral profile of this molecule. This is important, considering its safety and efficacy profile in HIV infected patients, who frequently suffer from co-infection. Compared with many other protease inhibitors, the reduced daily drug dosage and faster anti-viral effect of the drug mean far lower (if any) side effects and thus results in a far better quality of life for patients.